SLC5A2 and type 2 diabetes mellitus: In patients with ESKD with or without T2DM receiving maintenance PD, the use of SGLT-2 inhibitors in our small sample appears to be safe, as the AEs experienced by study participants were consistent with the currently known safety profile of the product.